Latest Celldex Therapeutics Stories

2008-11-12 12:00:31

Celldex Therapeutics, an integrated biopharmaceutical company, has signed an exclusive patent and know-how license agreement with the University of Southampton, UK, to develop human antibodies towards CD27, a potentially important target for immunotherapy of various cancers. In preclinical models, antibodies to CD27 have been shown to mediate anti-tumor effects alone, and may be particularly effective in combination with other immunotherapies. Financial terms of the transaction were not...

2008-11-04 03:00:05

Celldex Therapeutics, an integrated biopharmaceutical company, has announced initial results from multi-center Phase I clinical trials of its cancer vaccine candidate, CDX-1307, combined with GM-CSF. These data provide the basis for the ongoing assessment of CDX-1307 combined with more potent adjuvants with data expected in the first half of 2009. The Phase I studies are open-label, dose-escalating clinical trials in patients with incurable breast, bladder, pancreatic, or colorectal cancer,...

2008-10-03 09:00:38

Celldex Therapeutics, an integrated biopharmaceutical company, has received a milestone payment of $10 million from an affiliate of Paul Capital Healthcare. The payment was triggered by the market launch of Rotarix in the US. Rotarix is marketed worldwide by GlaxoSmithKline. John Leone, a partner at Paul Capital Healthcare, said: "In purchasing a portion of Celldex's Rotarix royalty stream, Paul Capital Healthcare has helped Celldex to monetize a previously under-appreciated asset. The...

Word of the Day
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.